Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
about
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasHuman IgG4: a structural perspectivePrinciples of antibody-mediated TNF receptor activationA perspective on the structure and receptor binding properties of immunoglobulin G FcSelective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor InteractionsStructural Determinants of Unique Properties of Human IgG4-FcImmunoglobulin G1 Fc Domain Motions: Implications for Fc EngineeringCrystal structure of deglycosylated human IgG4-FcImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesIgG1 Fc N-glycan galactosylation as a biomarker for immune activationInvestigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurementsDynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange.Restricted N-glycan conformational space in the PDB and its implication in glycan structure modeling.Glycoblocks: a schematic three-dimensional representation for glycans and their interactions.A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancyGlycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia.Protein post-translational modifications: In silico prediction tools and molecular modeling.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Development and Application of Multidimensional HPLC Mapping Method for O-linked Oligosaccharides.Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent CytotoxicityRestricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding.IgG subclasses and allotypes: from structure to effector functions.Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newbornStructure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding.Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.Loss of α1,6-Fucosyltransferase Decreases Hippocampal Long Term Potentiation: IMPLICATIONS FOR CORE FUCOSYLATION IN THE REGULATION OF AMPA RECEPTOR HETEROMERIZATION AND CELLULAR SIGNALING.A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.The Structural Role of Antibody N-Glycosylation in Receptor InteractionsBackbone (1)H, (13)C, and (15)N resonance assignments of the Fc fragment of human immunoglobulin G glycoproteinImportance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.Production of α2,6-sialylated IgG1 in CHO cellsCamelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform.Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.B-cell-independent sialylation of IgG.Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Glycans as targets for therapeutic antitumor antibodies.
P2860
Q26751002-6E941BB8-9B22-4F47-A79B-FE2CB00DAA5BQ26779758-CF425348-72FE-4FB5-AD25-21C6105CCAB9Q26796270-EA87F0FB-F433-4C7F-91A0-8F7BEEC196FFQ26827579-05547044-9E32-4F5D-B4ED-3247E066B044Q27678384-F5EFB91C-880B-49C9-AAAF-938889467233Q27680566-5BC4F45E-436D-46F0-9233-E35E4F0EA3B9Q27681704-1F969D52-1495-4940-9882-DC9A8A4E9BA6Q27684440-E552D0F6-3F8F-4B93-8FF8-3FE90E8C1F5CQ28069362-1EC17885-BEA3-4868-8838-4F7CA408DD23Q28601166-ED497F0C-86CC-487C-AF0C-507B20E69007Q30354666-4D9EC279-E8A7-4B1A-9C42-6ACB94378F73Q30357905-A9DCAFAF-32EF-4FA0-888B-04610C2F28CDQ30428551-B65ADC33-BAB5-4944-9FB3-5FD0E43361A0Q30837942-E785E54E-0639-4C6A-8FE8-0EDAD9E3FC9FQ33411528-871409E3-C06A-4116-86AD-5C98A092E40AQ33431066-626FFD5E-2488-49EC-9592-C1104B3C90A2Q33580119-03B4405A-8857-4FF8-ADE6-0C7C0A0A7EA0Q33621610-BE9F4FE5-43B2-414E-9257-832C9FB9B736Q33649454-F23C88E2-04B2-4056-826F-5EB9A6496507Q33766365-8C0F87B6-D4D4-4229-B3AD-C172C44744D0Q34315442-BFCE943A-65E7-4C59-95CE-CCEBFA73B0AAQ34368678-B741A924-8CDC-46CE-8535-E741D6C8A674Q34574913-7B807A75-BAC5-438D-A6CA-26AB2CF87E80Q34803358-3FF7CEB4-7B7E-43A4-B9E8-7FC939145820Q35031336-EE681190-3BEB-47D7-90F8-91AADBF2A0B8Q35705039-52CAD633-7B19-41CD-BCAE-6DEBD3867EABQ35837232-04D79FA2-47DB-4000-BE8C-08270300C285Q35886917-88048DD1-BD00-4663-8DC4-2173AE136B82Q36021825-2B8DCF96-595C-4E7D-B574-2CD7B48B1ECCQ36054689-02C3A45C-9B2B-4BD4-B38C-5EDF2AA21174Q36131665-8AAE6855-347A-4530-ACC4-7AAA5D27C4F2Q36213335-B20A2B21-05C2-4B07-B5A1-55828F874E28Q36214456-4250BD5D-2CE7-4CEC-AD63-F100ECD9FBDEQ36624176-5DCA82E8-4E3E-412B-BE8F-52BF8C6892AEQ36950893-E49F045F-650E-4221-A4AC-1BCA441E30B2Q37065114-C453B5CC-BB1C-4D89-8D49-767CBE416D8AQ37461186-3A576683-D8FC-46F1-BB2C-F374F5691302Q37496563-2059123C-F735-453C-9AF4-4F285D8347F2Q37677278-72A9108D-FE66-40B9-9E61-9E4013157FE9Q38034815-801171B7-DD93-4DE6-B948-7B9D25C105D2
P2860
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Structural basis for improved ...... cosylation of their Fc glycans
@ast
Structural basis for improved ...... cosylation of their Fc glycans
@en
Structural basis for improved ...... cosylation of their Fc glycans
@nl
type
label
Structural basis for improved ...... cosylation of their Fc glycans
@ast
Structural basis for improved ...... cosylation of their Fc glycans
@en
Structural basis for improved ...... cosylation of their Fc glycans
@nl
prefLabel
Structural basis for improved ...... cosylation of their Fc glycans
@ast
Structural basis for improved ...... cosylation of their Fc glycans
@en
Structural basis for improved ...... cosylation of their Fc glycans
@nl
P2093
P2860
P3181
P1433
P1476
Structural basis for improved ...... cosylation of their Fc glycans
@en
P2093
Emi Takemoto
Hirokazu Yagi
Kazuhiro Masuda
Koichi Kato
Mami Shibata-Koyama
Mitsuo Satoh
Shigeru Iida
Tsunehiro Mizushima
Yuya Isoda
P2860
P304
P3181
P356
10.1111/J.1365-2443.2011.01552.X
P577
2011-11-01T00:00:00Z